NMI 8000 companion diagnostic - Allarity Therapeutics
Latest Information Update: 12 Oct 2020
At a glance
- Originator Nemucore Medical Innovations
- Developer Nemucore Medical Innovations; Oncology Venture A/S
- Class Diagnostic agents
- Mechanism of Action Anti-Mullerian hormone receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 07 Oct 2020 Oncology Venture A/S is now called Allarity Therapeutics
- 26 Feb 2019 Discontinued - Phase-II for Solid tumours (Diagnosis) in USA (Nemucore Medical Innovations pipeline, February 2019)
- 24 Aug 2018 Medical Prognosis Institute merged with Oncology Venture and the former changed its name to Oncology Venture A/S